Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11186637 Anti-PD1 antibodies and their use as therapeutics and diagnostics

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Qi Liu0

Kang Li0

Lanlan Xu0

Tong Zhang0

Hao Peng0

Jing Song0

Date of Patent

November 30, 2021

0

Patent Application Number

171546960

Date Filed

January 21, 2021

0

Patent Citations Received

US Patent 11786529 Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors

US Patent 11512132 Anti-PD-L1 antibodies and their use as therapeutics and diagnostics

0

US Patent 11534431 Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer

0

US Patent 11597768 Immunotherapy for hepatocellular carcinoma

US Patent 11701357 Treatment of B cell cancers using a combination comprising Btk inhibitors

0

Patent Primary Examiner

0

Patent abstract

Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11186637 Anti-PD1 antibodies and their use as therapeutics and diagnostics

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool